Condition or disease |
---|
Severe Infection and Non-injury Death |
Study Type : | Observational |
Estimated Enrollment : | 3000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Severe Infections and the Intestinal Microbiome in Young Infants in Dhaka, Bangladesh: an Observational Cohort Study |
Actual Study Start Date : | February 12, 2020 |
Estimated Primary Completion Date : | November 2021 |
Estimated Study Completion Date : | November 2021 |
Severe infection is defined as at least one sign of clinical severe infection (CSI) (i.e., poor feeding, lethargy, convulsions, severe chest in-drawing, fever, or hypothermia) documented by a physician and/or physician diagnosis of sepsis or another serious bacterial infection (SBI); and at least one of the following two criteria: 1) physician decision to admit to hospital, administration of at least one dose of a parenteral antibiotic on the day when CSI/sepsis/SBI is first ascertained, and treatment (or physician intention to treat) with parenteral antibiotics for at least 5 days or 2) blood and/or cerebrospinal fluid (CSF) culture positive for a pathogenic bacterial or fungal organism.
Non-injury death refers to death due to any cause except death that was directly caused by physical trauma (medically certified cause of death and/or verbal autopsy).
Routine specimen collection:
Specimen collection triggered by presence of clinical severe infection (CSI): infant stool, nasal swab, blood, urine; and, skin swabs and cerebrospinal fluid (CSF) at treating physician's discretion.
Nasal swabs will also be collected from infants with LRTI (fast breathing with at least one of cough, nasal congestion, or runny nose) or in hospitalized infants with diarrhea and/or vomiting.
Ages Eligible for Study: | up to 49 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Core Inclusion Criteria:
Core Exclusion Criteria:
Contact: Daniel Roth | 4168137654 ext 328807 | daniel.roth@sickkids.ca |
Bangladesh | |
Maternal Child Health Training Institute | Recruiting |
Dhaka, Bangladesh | |
Mohammadpur Fertility Services Training Centre | Recruiting |
Dhaka, Bangladesh |
Principal Investigator: | Daniel Roth | The Hospital for Sick Children |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | June 19, 2019 | ||||
First Posted Date | July 9, 2019 | ||||
Last Update Posted Date | March 10, 2021 | ||||
Actual Study Start Date | February 12, 2020 | ||||
Estimated Primary Completion Date | November 2021 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
|
||||
Original Primary Outcome Measures |
|
||||
Change History | |||||
Current Secondary Outcome Measures | Not Provided | ||||
Original Secondary Outcome Measures | Not Provided | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | SEPSIS Observational Cohort Study in Young Infants in Bangladesh | ||||
Official Title | Severe Infections and the Intestinal Microbiome in Young Infants in Dhaka, Bangladesh: an Observational Cohort Study | ||||
Brief Summary | Globally, infectious diseases such as sepsis, meningitis and pneumonia are among the leading causes of neonatal deaths. A recent observational study in South Asia highlighted the contribution of both bacterial and viral infections to the burden of illness in infants <60 days of age; however, there remains a need to quantify the risk of severe infection (SI) among newborns in a Bangladeshi population. In collaboration with researchers in Bangladesh, investigators aim to generate knowledge regarding the incidence and risk factors of SI, including the composition of the intestinal microbiome, in young infants (birth to 60 days of age) in Dhaka, Bangladesh. Data will support the design and implementation of future trials to test the efficacy of novel interventions for the prevention of SI in young infants, to promote optimal growth and development, and to determine effects on other health outcomes in early infancy. | ||||
Detailed Description |
Globally, infectious diseases including sepsis, meningitis, and pneumonia are among the leading causes of neonatal deaths. In 2017, these three conditions were estimated to account for 540,000 newborn deaths worldwide, approximately 21% of all neonatal deaths globally. Previous studies have suggested that South Asia has a relatively high incidence of possible serious bacterial infection (pSBI) in young infants, particularly in areas where neonatal and under-five mortality rates are highest. A large body of evidence from inpatient neonatal populations, and the recent evidence from the Panigrahi et al. community trial in India, support an important role of intestinal dysbiosis in the pathogenesis of sepsis/SI in young infants. This mechanism may be particularly important in low- and middle-income countries in Africa and South Asia, where low-cost routine interventions to reduce the burden of SI (e.g., probiotics or synbiotics) could have an important impact on the burden of morbidity and mortality in young infants. However, there are limited data regarding the composition of the early postnatal microbiome in the general population of infants (rather than selected groups of preterm or hospitalized newborns) in South Asia and the role of the microbiome in modulating the risk of SI. This observational study will generate new knowledge about the incidence and risk factors of SI, including the composition of the intestinal microbiome, in young infants (birth to 60 days of age) in Dhaka, Bangladesh. The aims of this study are to:
Study personnel will conduct active and passive clinical surveillance and routine specimen collection (e.g. stool, nasal, skin and oral swabs etc.). Additional specimen collection may also be triggered in the event of physician-confirmed clinical severe infection, or if infants meet the case definition of LRTI (fast breathing with at least one of the following: cough, nasal congestion, or runny nose) or are hospitalized with diarrhea and/or vomiting. |
||||
Study Type | Observational | ||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Retention: Samples With DNA Description:
Routine specimen collection:
Specimen collection triggered by presence of clinical severe infection (CSI): infant stool, nasal swab, blood, urine; and, skin swabs and cerebrospinal fluid (CSF) at treating physician's discretion. Nasal swabs will also be collected from infants with LRTI (fast breathing with at least one of cough, nasal congestion, or runny nose) or in hospitalized infants with diarrhea and/or vomiting. |
||||
Sampling Method | Non-Probability Sample | ||||
Study Population | Healthy Bangladeshi newborns, delivered at two public hospitals (Maternal and Child Health Training Institute and Mohammadpur Fertility Services and Training Centre), and their mothers in Dhaka, Bangladesh. Newborns will be enrolled between 0 and 4 days postnatal age (n=3,000). | ||||
Condition | Severe Infection and Non-injury Death | ||||
Intervention | Not Provided | ||||
Study Groups/Cohorts | Not Provided | ||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Recruiting | ||||
Estimated Enrollment |
3000 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | November 2021 | ||||
Estimated Primary Completion Date | November 2021 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria |
Core Inclusion Criteria:
Core Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | up to 49 Years (Child, Adult) | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts |
|
||||
Listed Location Countries | Bangladesh | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT04012190 | ||||
Other Study ID Numbers | 1000063899 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement | Not Provided | ||||
Responsible Party | Daniel Roth, The Hospital for Sick Children | ||||
Study Sponsor | The Hospital for Sick Children | ||||
Collaborators |
|
||||
Investigators |
|
||||
PRS Account | The Hospital for Sick Children | ||||
Verification Date | March 2021 |